Add Company
Join Now

ImmuneSensor Therapeutics Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ImmuneSensor Therapeutics's estimated annual revenue is currently $775k per year.(i)
  • ImmuneSensor Therapeutics's estimated revenue per employee is $77,500

Employee Data

  • ImmuneSensor Therapeutics has 10 Employees.(i)
  • ImmuneSensor Therapeutics grew their employee count by -17% last year.

ImmuneSensor Therapeutics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M11-8%N/AN/A
#2
$14.9M96-6%N/AN/A
#3
$15.2M983%$1.8MN/A
#4
$1.6M100%N/AN/A
#5
$3.4M220%N/AN/A
#6
$2.8M1850%N/AN/A
#7
$7.4M48-2%N/AN/A
#8
$0.8M50%N/AN/A
#9
$1.6M100%N/AN/A
#10
$16.3M10562%N/AN/A
Add Company

What Is ImmuneSensor Therapeutics?

ImmuneSensor is developing novel medicines that target the cGAS (cyclic GMP-AMP synthase) - STING (stimulator of interferon genes) pathway of the innate immune system to treat cancer and autoimmune diseases. The Company has licensed technologies from the laboratory of Dr. Zhijian \James\ Chen, Professor of Molecular Biology at the University of Texas Southwestern Medical Center and Investigator of Howard Hughes Medical Institute. Dr. Chen discovered cGAS and its product cGAMP, which activates STING to stimulate immune responses. These discoveries form the technological foundation of ImmuneSensor. The company's pipeline consists of both STING activators to boost anticancer immunity and also cGAS inhibitors to suppress overactivated autoimmunity. ImmuneSensor's lead program, IMSA101 is a STING activator currently in clinical development for cancer therapy.

keywords:N/A

N/A

Total Funding

10

Number of Employees

$775k

Revenue (est)

-17%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.5M10-9%N/A
#2
$1M10-33%N/A
#3
$1.8M10N/AN/A
#4
$0.9M10N/AN/A
#5
$0.9M10N/AN/A